Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab (HLX02) + aromatase inhibitor versus trastuzumab (HLX02) + aromatase inhibitor for HR-positive/HER2-positive metastatic breast cancer
ChiCTR2300076669Phase 4Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pyrotinib and trastuzumab in breast cancer (2 arms), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-free survival. Started Sep 2023; status: recruiting.
02
Drugs
pyrotinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300076669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076669.